Efficacy Results of a Trial of a Herpes Simplex Vaccine

Rhoda L. Ashley Morrow, Thomas C. Heineman, Abbie Stokes-Riner, Iris Gorfinkel, Robert B. Belshe, Jack T. Stapleton, Peter A. Leone, Myron J. Levin, David I. Bernstein, Carolyn D. Deal, Gary Dubin, Marian G. Ewell (+2 others)
Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negative for both HSV type 1 (HSV-1) and HSV-2 antibodies. Efficacy was not observed in men or HSV-1 seropositive women.
doi:10.17615/zd06-bd20 fatcat:g7stf5tyyndevo7ouwrx7fzfii